|Presentation title||Abstract number / presentation times(all times listed are Eastern Standard Time)|
|Efficacy and Safety of Tocilizumab in Patients with Giant Cell Arteritis: Primary and Secondary Outcomes from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial (Stone J, et al.)||Oral presentationAbstract ID: 911Sunday, November 1311:00 a.m. - 12:30 p.m.|
|Safety and Efficacy of Subcutaneous Tocilizumab in Early Systemic Sclerosis: Results from the Open-Label Period of a Phase 2 Randomized, Controlled Trial (Khanna D, et al.)||Oral presentationAbstract ID: 969Sunday, November 132:30 - 4:00 p.m.|
|Comparative Cardiovascular Safety of Tocilizumab vs. Etanercept in Rheumatoid Arthritis: Results of a Randomized, Parallel-Group, Multicenter, Noninferiority, Phase 4 Clinical Trial (Giles JT, et al.)||Oral presentationAbstract ID: 3LTuesday, November 154:30 - 6:00 p.m.|
|Comparative Effectiveness of Tocilizumab Monotherapy with Tumor Necrosis Factor Inhibitors in Combination with Methotrexate in Patients with Rheumatoid Arthritis and Prior Exposure to Tumor Necrosis Factor Inhibitors (Harrold L, et al.)||Poster presentationAbstract ID: 1596Monday, November 149:00 - 11:00 a.m.|
|Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis (Kim SC, et al.)||Poster presentationAbstract ID: 2611Tuesday, November 159:00 - 11:00 a.m.|
|Methotrexate Adherence in an Online Network of Patients with Rheumatoid Arthritis (Katic B, et al.)||Poster presentationAbstract ID: 2532Tuesday, November 159:00 - 11:00 a.m.|
|Patient-Reported Outcomes in Two Randomized, Controlled Trials (RCTs) in Patients with Rheumatoid Arthritis (RA) Treated with Tocilizumab (TCZ) Monotherapy Compared with Methotrexate (MTX) or Adalimumab (ADA) (Strand V, et al.)||Poster presentationAbstract ID: 2515Tuesday, November 159:00 - 11:00 a.m.|
|Factors Associated with Glucocorticoid Exposure in ANCA-Associated Vasculitis (Cascino MD, et al.)||Poster presentationAbstract ID: 1930Monday, November 149:00 - 11:00 a.m.|
|Impact of Rituximab on Patient-Reported Outcomes in Patients with Rheumatoid Arthritis from the U.S. Corrona Registry (Harrold L, et al.)||Poster presentationAbstract ID: 1580Monday, November 149:00 - 11:00 a.m.|
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that new data from Actemra ® (tocilizumab) and Rituxan ® (rituximab) will be presented during the 2016 American College of Rheumatology (ACR) and Association for Rheumatology Health Professionals (ARHP) Annual Meeting, November 11-16, Washington, D.C. These data add to the significant body of evidence for Actemra and Rituxan in RA and other serious immune-mediated conditions including GCA, systemic sclerosis (SSc), granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). "Advances in our scientific understanding behind immune pathways are guiding the development of potential new treatments for severe autoimmune conditions," said Sandra Horning, M.D., chief medical officer and head of Global Product Development. "Building on our more than a decade of experience in providing treatment options for people suffering from rheumatologic conditions, we look forward to sharing new data at this year's ACR/ARHP meeting." At this meeting, key presentations from Genentech will include: the first efficacy and safety results from GiACTA - a study investigating Actemra in GCA, an often chronic, potentially life-threatening autoimmune condition; ENTRACTE, a Phase IV study in patients with RA evaluating the risk of cardiovascular (CV) events with Actemra in comparison to etanercept; a real world data analysis of CV outcomes in RA patients who switched from another biologic agent to either Actemra or a tumor necrosis factor inhibitor (TNFi); plus further insights into the use of Actemra in SSc. Additionally, treatment insights from Rituxan in RA and GPA/MPA will also be presented. Overview of key oral and poster presentations featuring Genentech medicines at the 2016 ACR/ARHP Annual Meeting. Please note that in accordance with the meeting's policy, all abstract data is strictly embargoed until November 12, 2016, 4:30 PM ET.
Follow Genentech on Twitter via @genentech. Keep up with ACR 2016 news and updates by following the event's hashtag #ACR16. About Actemra Actemra is the first humanized interleukin-6 (IL-6) receptor antagonist approved for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have used one or more disease-modifying antirheumatic drugs (DMARDs), such as methotrexate (MTX), that did not provide enough relief. The extensive Actemra RA IV clinical development program included five Phase III clinical studies and enrolled more than 4,000 people with RA in 41 countries. The Actemra RA subcutaneous clinical development program included two Phase III clinical studies and enrolled more than 1,800 people with RA in 33 countries. In addition, Actemra is also used as an IV formulation for patients with active polyarticular juvenile idiopathic arthritis (PJIA) or systemic juvenile idiopathic arthritis (SJIA) two years of age and older. Actemra is not approved for subcutaneous use in people with PJIA or SJIA.